Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Jul;62(1):45-55.
doi: 10.1093/jac/dkn165. Epub 2008 Apr 24.

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

Drosos E Karageorgopoulos  1 , Theodore Kelesidis, Iosif Kelesidis, Matthew E Falagas
Affiliations
Review

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

Drosos E Karageorgopoulos et al. J Antimicrob Chemother. 2008 Jul.

Abstract

Objectives: New antibacterial agents are required for the treatment of infections caused by multidrug-resistant (MDR) Acinetobacter spp. Whether tigecycline constitutes an effective treatment option or not, is not well established. We sought to evaluate the available evidence regarding the microbiological activity and clinical effectiveness of tigecycline for MDR (including the subset of carbapenem-resistant) Acinetobacter spp.

Methods: We searched PubMed for relevant articles and extracted/evaluated the available evidence.

Results: We identified 22 microbiological studies reporting data for 2384 Acinetobacter spp. (1906 Acinetobacter baumannii). Susceptibility of at least 90% of the Acinetobacter isolates to tigecycline (with an MIC breakpoint of susceptibility < or =2 mg/L) was noted in 9/18 studies reporting data on MDR Acinetobacter and in 7/15 studies reporting specific data on carbapenem-resistant Acinetobacter. In an additional study reporting data for both resistance categories, adequate susceptibility of Acinetobacter spp. was observed by one (broth microdilution) of the methods employed. The effectiveness of tigecycline for MDR Acinetobacter infections was evaluated in eight identified clinical studies, reporting retrospective data regarding 42 severely ill patients, among whom 31 had respiratory tract infection (in 4 cases with secondary bacteraemia) and 4 had bacteraemia. Tigecycline therapy (in combination with other antibiotics in 28 patients) was effective in 32/42 cases. In three cases, resistance to tigecycline developed during treatment.

Conclusions: Tigecycline showed considerable, though not consistent, antimicrobial activity against MDR (including carbapenem-resistant) Acinetobacter spp. However, data to support its clinical use, particularly for ventilator-associated pneumonia or bacteraemia, caused by these pathogens, are still limited.

Trial registration: ClinicalTrials.gov NCT00080496.

PubMed Disclaimer

References

    1. Van Looveren M, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684–704. - PubMed
    1. Houang ET, Chu YW, Leung CM et al. Epidemiology and infection control implications of Acinetobacter spp. in Hong Kong. J Clin Microbiol 2001; 39: 228–34. - PMC - PubMed
    1. Seifert H, Baginski R, Schulze A et al. The distribution of Acinetobacter species in clinical culture materials. Zentralbl Bakteriol 1993; 279: 544–52. - PubMed
    1. Tjernberg I, Ursing J. Clinical strains of Acinetobacter classified by DNA-DNA hybridization. APMIS 1989; 97: 595–605. - PubMed
    1. Cisneros JM, Reyes MJ, Pachon J et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22: 1026–32. - PubMed

MeSH terms

Associated data